Explore
Validate
Learn55201-1-AP
antibody from Proteintech Group
Targeting: SET
2PP2A, IGAAD, IPP2A2, PHAPII, TAF-I, TAF-IBETA
Western blot
ELISAAntibody data
- Antibody Data
- Antigen structure
- References [5]
- Comments [0]
- Validations
- Western blot [1]
- Immunohistochemistry [2]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 55201-1-AP - Provider product page
- Provider
- Proteintech Group
- Proper citation
- Proteintech Cat#55201-1-AP, RRID:AB_10837360
- Product name
- SET/TAF-I antibody
- Antibody type
- Polyclonal
- Description
- KD/KO validated SET/TAF-I antibody (Cat. #55201-1-AP) is a rabbit polyclonal antibody that shows reactivity with human and has been validated for the following applications: IHC, WB,ELISA.
- Reactivity
- Human
- Host
- Rabbit
- Conjugate
- Unconjugated
- Isotype
- IgG
- Vial size
- 20ul, 150ul
Submitted references MicroRNA-1915-3p inhibits cell migration and invasion by targeting SET in non-small-cell lung cancer.
Overexpression of SET oncoprotein is associated with tumor progression and poor prognosis in human gastric cancer.
Overexpression of PP2A inhibitor SET oncoprotein is associated with tumor progression and poor prognosis in human non-small cell lung cancer.
SET-mediated NDRG1 inhibition is involved in acquisition of epithelial-to-mesenchymal transition phenotype and cisplatin resistance in human lung cancer cell.
Reactivating PP2A by FTY720 as a novel therapy for AML with C-KIT tyrosine kinase domain mutation.
Pan H, Pan Z, Guo F, Meng F, Zu L, Fan Y, Li Y, Li M, Du X, Zhang X, Shao Y, Wei M, Li X, Zhou Q
BMC cancer 2021 Nov 13;21(1):1218
BMC cancer 2021 Nov 13;21(1):1218
Overexpression of SET oncoprotein is associated with tumor progression and poor prognosis in human gastric cancer.
Yuan X, Zhang T, Zheng X, Zhang Y, Feng T, Liu P, Sun Z, Qin S, Liu X, Zhang L, Song J, Liu Y
Oncology reports 2017 Sep;38(3):1733-1741
Oncology reports 2017 Sep;38(3):1733-1741
Overexpression of PP2A inhibitor SET oncoprotein is associated with tumor progression and poor prognosis in human non-small cell lung cancer.
Liu H, Gu Y, Wang H, Yin J, Zheng G, Zhang Z, Lu M, Wang C, He Z
Oncotarget 2015 Jun 20;6(17):14913-25
Oncotarget 2015 Jun 20;6(17):14913-25
SET-mediated NDRG1 inhibition is involved in acquisition of epithelial-to-mesenchymal transition phenotype and cisplatin resistance in human lung cancer cell.
Liu H, Gu Y, Yin J, Zheng G, Wang C, Zhang Z, Deng M, Liu J, Jia X, He Z
Cellular signalling 2014 Dec;26(12):2710-20
Cellular signalling 2014 Dec;26(12):2710-20
Reactivating PP2A by FTY720 as a novel therapy for AML with C-KIT tyrosine kinase domain mutation.
Yang Y, Huang Q, Lu Y, Li X, Huang S
Journal of cellular biochemistry 2012 Apr;113(4):1314-22
Journal of cellular biochemistry 2012 Apr;113(4):1314-22
No comments: Submit comment
Supportive validation
- Submitted by
- Proteintech Group (provider)
- Main image
- Experimental details
- HeLa cells were subjected to SDS PAGE followed by western blot with 55201-1-AP(SET antibody) at dilution of 1:1000
- Sample type
- cell line
Supportive validation
- Submitted by
- Proteintech Group (provider)
- Main image
- Experimental details
- Immunohistochemical of paraffin-embedded human liver cancer using 55201-1-AP(SET antibody) at dilution of 1:100 (under 10x lens)
- Sample type
- tissue
- Submitted by
- Proteintech Group (provider)
- Main image
- Experimental details
- The SET antibody from Proteintech is a rabbit polyclonal antibody to a peptide of human SET. This antibody recognizes human, mouse, rat antigen. The SET antibody has been validated for the following applications: ELISA, WB, IHC analysis.
